<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm -->
<html class="" data-reactroot=""><script async="false" type="text/javascript" src="chrome-extension://fnjhmkhhmkbjkkabndcnnogagogbneec/in-page.js"></script><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./1121.抗磷脂综合征 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app227.us.archive.org';v.server_ms=497;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d11121.htm","20221029032955","https://web.archive.org/","web","/_static/",
	      "1667014195");
</script>
<link rel="stylesheet" type="text/css" href="./1121.抗磷脂综合征 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./1121.抗磷脂综合征 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="抗磷脂综合征 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032955/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221029032955im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./1121.抗磷脂综合征 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./1121.抗磷脂综合征 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./1121.抗磷脂综合征 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./1121.抗磷脂综合征 - 搜狗科学百科_files/highlight.min.css"><title>抗磷脂综合征 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style>
<!--百度统计-->
<script>
   var _hmt = _hmt || [];
   (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
      var s = document.getElementsByTagName("script")[0]; 
      s.parentNode.insertBefore(hm, s);
      })();
</script>
</head>
<body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d11121.htm","20221029032955",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('825be3e86cf3466c98c93cf20ffb52c6') window._gtag.traceId = '825be3e86cf3466c98c93cf20ffb52c6';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221029032955/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221029032955/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221029032955/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221029032955/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221029032955/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221029032955/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221029032955/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221029032955/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221029032955/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value="" control-id="ControlID-1"><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>抗磷脂综合征</h1><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="52058398765664523"><div><p><b>抗磷脂综合征或抗磷脂抗体综合征(APS或APLS)</b>，是由抗磷脂抗体引起的自身免疫性高凝状态。APS导致动静脉血栓形成以及妊娠相关并发症，如流产、死产、早产和重度子痫前期。诊断标准需要一个临床表现(即血栓形成或妊娠并发症)和两项相隔至少三个月的血清抗体实验室检查，包括狼疮抗凝物或抗β2-糖蛋白-1(由于β2-糖蛋白-1抗体属于抗心磷脂抗体，抗心磷脂试验可以作为替代实验)<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_1" class="kx_ref">[1]</a></sup>。</p>
<p>抗磷脂综合征分为原发性和继发性。原发性抗磷脂综合征是指没有任何其他相关疾病所致的抗磷脂综合征。继发性抗磷脂综合征继发于其他自身免疫性疾病，如系统性红斑狼疮。在极少数情况下，APS会因全身血栓形成而导致快速器官衰竭；被称为“灾难性抗磷脂综合征”(CAPS或Asherson综合征)，与高死亡风险相关。</p>
<p>抗磷脂综合征通常需要采用抗凝药物进行治疗，如肝素，以降低进一步血栓形成的风险，并改善妊娠预后。与肝素不同，妊娠期间，不使用华法林/香豆素，因为它可以穿过胎盘，并且具有致畸作用。</p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col2"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14996343411966475">症状和体征</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14996343411966476">风险因素</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14996343411966477">发病机制</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14996343411966478">诊断</a></li><li class="secondary_catalog"><span>4.1 </span><a href="javascript:" data-id="14996343411966478"><b>狼疮抗凝物</b></a></li><li class="secondary_catalog"><span>4.2 </span><a href="javascript:" data-id="14996343411966478"><b>抗心磷脂抗体</b></a></li><li class="secondary_catalog"><span>4.3 </span><a href="javascript:" data-id="14996343411966478"><b>诊断标准</b></a></li></ul><ul class="catalog_list col2"><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14996343428743687">治疗</a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="14996343428743688">预后</a></li><li><span class="order">7</span><a href="javascript:" data-level="1" data-id="14996343428743689">历史</a></li><li><span class="order">8</span><a href="javascript:" data-level="1" data-id="14996343445520896">研究</a></li><li><span class="order">9</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14996343411966475"><h2 class="title">1 症状和体征<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>在没有血栓或妊娠相关并发症的情况下，抗磷脂抗体(aPL)阳性不能诊断APS(APS的诊断见下文)。抗磷脂综合征可在任何器官系统中引起动脉或静脉血栓，或妊娠相关并发症。APS患者中，最常见的静脉血栓是下肢深静脉血栓形成，最常见的动脉血栓是卒中。在受APS影响的孕妇中，反复流产、宫内生长受限和早产的风险增加。这些并发症的常见原因是胎盘梗塞。在某些情况下，APS是新生儿智力和/或发育迟缓的主要原因，机制是aPL抑制滋养层细胞的分化。在妊娠合并系统性红斑狼疮的患者中，抗磷脂综合征是大多数妊娠晚期流产的原因<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_2" class="kx_ref">[2]</a></sup>。</p><p>其他常见的临床，虽然不属于APS诊断标准的一部分，但包括血小板计数减少、心脏瓣膜疾病和网状青斑。抗磷脂抗体也可以引起头痛、偏头痛和振动幻视<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_3" class="kx_ref">[3]</a></sup>。一些研究表明，有神经精神症状的患者血液和脑脊液中存在抗磷脂抗体<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_4" class="kx_ref">[4]</a></sup>。</p><p>很少有原发性抗磷脂抗体综合征患者继续发展成系统性红斑狼疮。</p></div></div><div id="par_14996343411966476"><h2 class="title">2 风险因素<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>抗磷脂综合征的危险因素包括:</p><p>
 </p><ul>
  <li>原发性APS
   <ul>
    <li>遗传标记 HLA-DR7</li>
   </ul></li>
  <li>继发性APS
   <ul>
    <li>系统性红斑狼疮或其他自身免疫性疾病</li>
    <li>遗传标记:人类白细胞抗原-B8，人类白细胞抗原-DR2，人类白细胞抗原-DR3</li>
    <li>种族:黑人、西班牙裔、亚洲人和美洲原住民</li>
   </ul></li>
 </ul><p></p><p>肾上腺出血导致沃特豪斯-弗里德里希森综合征(脑膜炎奈瑟菌引起原发性肾上腺功能不全)的风险增加。这需要终身采用肾上腺类固醇替代治疗。</p></div></div><div id="par_14996343411966477"><h2 class="title">3 发病机制<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>抗磷脂综合征是一种自身免疫性疾病，其中“抗磷脂抗体”(抗心磷脂抗体和狼疮抗凝物抗体)与细胞膜上带负电荷磷脂的蛋白质发生反应。像许多自身免疫性疾病一样，女性比男性更常见。确切原因尚不清楚，但凝血系统的激活是明确的。临床上重要的抗磷脂抗体(由自身免疫过程产生的抗体)与血栓形成和血管疾病相关。该综合征可分为原发性(无原发病)和继发性(与原发病相关)。</p><p>抗ApoH和一些抗心磷脂抗体与ApoH结合，进而抑制蛋白C，蛋白C是凝血共同通路途径上具有调节功能的糖蛋白(降解活化V因子)。</p><p>凝血酶是凝血酶原的活性形式，狼疮抗凝物抗体结合凝血酶原，从而增加其对凝血酶的裂解。</p><p>在APS中也有抗体结合蛋白S，蛋白S是蛋白C的一个协同因子。因此，抗蛋白S抗体能降低蛋白C的活性<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_5" class="kx_ref">[5]</a></sup>。</p><p>膜联蛋白A5在带负电荷的磷脂分子周围形成屏障，从而抑制凝血。因此，抗膜联蛋白A5抗增强了磷脂依赖性凝血过程<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_6" class="kx_ref">[6]</a></sup>。</p><p>狼疮抗凝物抗体与血栓形成密切相关，其中靶向β2糖蛋白1的抗体比靶向凝血酶原的抗体与血栓形成关系更密切。抗心磷脂抗体在中高滴度(&gt; 40GPLU或MPLU)时与血栓形成相关。狼疮抗凝物抗体和中/高滴度抗心磷脂抗体的患者比单一抗体的患者血栓形成风险更高。</p><p>体外研究证实，抗磷脂抗体导致反复流产、宫内生长受限和早产的风险增加，包括滋养层细胞活性、合胞体化和侵袭功能降低、滋养层激素和信号分子的紊乱，以及凝血和补体途径的激活<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_7" class="kx_ref">[7]</a></sup>。</p></div></div><div id="par_14996343411966478"><h2 class="title">4 诊断<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>抗磷脂综合征的抗体实验室检查分别采用液相凝血试验(狼疮抗凝物)和固相酶联免疫吸附试验(抗心磷脂抗体)。</p><p>遗传性血栓形成倾向是APS鉴别诊断的一部分，在一些APS患者中可以共存。遗传性血栓形成倾向可能需要抗凝治疗。因此，遗传性血栓形成倾向筛查可包括:</p><p>
 </p><ul>
  <li>进一步研究莱顿V因子变异体和凝血酶原G20210A突变，VIII因子水平，甲氨蝶呤突变。</li>
  <li>l 蛋白C、游离蛋白和总蛋白S、VIII因子、抗凝血酶、纤溶酶原、组织纤溶酶原激活物（TPA）和纤溶酶原激活物抑制剂-1(PAI-1)的水平。</li>
 </ul><p></p><p>抗aPL的个体靶标如β2糖蛋白1和抗磷脂酰丝氨酸的抗体检测目前正在争论中，因为目前抗心磷脂的检测对APS的诊断是敏感和特异的，虽然抗心磷脂抗体在体内并不被认为是抗磷脂抗体的靶标。</p><p></p><h3>4.1 <span>狼疮抗凝物</span></h3><p></p><p>由于狼疮抗凝物抗体的异质性，至少通过使用两种磷脂敏感的凝血试验来检测。通常在初始筛查的患者中APTT会有延长，延长的APTT在与正常人血浆的80∶20混合物中不能被修正(与正常血浆的50∶50混合物，除了对最高抗体水平敏感外，其余所有抗体水平都不敏感)。APTT(加80:20混合比例)、Russell蝰蛇毒液稀释时间(DRVVT)、白陶土凝固时间(KCT)、稀释凝血活酶时间(TDT/DTT)、二氧化硅凝固时间(SCT)<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_7" class="kx_ref">[7]</a></sup> 和凝血酶原时间(使用狼疮敏感凝血活酶)是用于检测狼疮抗凝物的主要实验。这些检测必须至少进行两次且间隔至少6周，每次均阳性，才能诊断抗磷脂综合征。这是为了防止一过性的阳性结果(由于感染等原因)被被误诊为抗磷脂综合征。</p><p>将狼疮抗体与特定凝血因子抑制剂(如VIII因子)区分开来，通常是通过测定狼疮抗凝物与特定凝血因子抗体对凝血因子影响的区别来实现的。狼疮抗凝物将抑制所有接触激活凝血途径因子(VIII因子、IX因子、XI因子和XII因子)。狼疮抗凝物很少导致凝血因子水平低于35 iu/dl (35%)，而特定凝血因子抗体则很少高于10 iu/dl (10%)。由于狼疮抗凝物对凝血功能的影响，可以采用APTT比监测静脉抗凝剂治疗效果，在这些情况下，采用肝素介导的抗凝血酶对Xa因子的抑制显色的检测方法是最好的。</p><p></p><h3>4.2 <span>抗心磷脂抗体</span></h3><p></p><p>抗心磷脂抗体可采用酶联免疫吸附试验(ELISA)进行检测，该试验筛选β2糖蛋白1依赖性抗心磷脂抗体。</p><p>在抗心磷脂阳性患者中中也可以观察到血小板计数减少和抗β2-糖蛋白1或磷脂酰丝氨酸抗体的阳性。</p><p></p><h3>4.3 <span>诊断标准</span></h3><p></p><p>APS的诊断标准需要一个或多个特定的、确切的临床表现(血栓形成和/或产科不良事件)和aPL重复阳性的实验室结果。APS札幌诊断标准(1998年，1999年出版)在2006年被悉尼标准取代<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_8" class="kx_ref">[8]</a></sup>。根据最新标准，APS的诊断需要一种临床表现和一种实验室结果:</p><p>
 </p><ul>
  <li>临床表现
   <ul>
    <li>依据客观诊断标准，任何组织或器官中动脉、静脉或小血管血栓形成(浅静脉血栓形成除外)，且无血管炎表现。</li>
    <li>1次或以上形态正常胎儿(通过超声或胎儿直接检查确诊)在妊娠第10周或之后不明原因死亡，和/或排除母体解剖或激素异常以及父系和母系染色体原因，3次或以上妊娠第10周之前不明原因连续自然流产，或至少1次形态正常新生儿在妊娠第34周之前因子痫或重度子痫前期早产，或胎盘功能不全。</li>
   </ul></li>
  <li>实验室检查:
   <ul>
    <li>用标准化的酶联免疫吸附测定法测定抗心磷脂抗体，IgG&nbsp; 和/或IgM抗体2次或更多次，间隔不少于12周，结果为中高滴度(即&gt; 40 GPL 或 MP，L或&gt;第99百分位)</li>
    <li>用标准化酶联免疫吸附试验测定抗β2糖蛋白抗体，IgG和/或IgM 2次或更多次，间隔不少于12周，结果为中高滴度(&gt;第99百分位)</li>
    <li>根据国际血栓形成和止血学会指南，狼疮抗凝物检测间隔不少于12周。</li>
   </ul></li>
 </ul><p></p><p>APS分为三类:原发性(不伴有其他疾病)、继发性(既往有自身免疫性疾病，最常见的是系统性红斑狼疮(SLE))和灾难性(伴随多器官功能衰竭和小血管闭塞)。</p><p>根据2006年的共识<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_8" class="kx_ref">[8]</a></sup>，出于研究目的，建议将APS按如下标准分类:</p><p>
 </p><ul>
  <li>I:一个以上的实验室诊断标准；</li>
  <li>IIa:狼疮抗凝物单独存在</li>
  <li>IIb:中高度抗心磷脂IgG和/或IgM单独存在</li>
  <li>IIc:抗β2糖蛋白IgG和/或IgM单独存在，滴度大于99%</li>
 </ul><p></p><p>该国际共识通常用于灾难性APS诊断<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_9" class="kx_ref">[9]</a></sup>。基于这一共识，CAPS诊断包括以下标准:</p><p>
 </p><ul>
  <li>三个或更多器官或组织中血栓形成</li>
  <li>同时或在不到一周的时间内出现临床症状</li>
  <li>至少一个器官或组织中有小血管血栓形成的表现</li>
  <li>实验室确诊aPL阳性。</li>
 </ul><p></p><p>VDRL，用于检测梅毒抗体的实验，在aPL阳性患者中可能会有假阳性结果(aPL在检测中与脂质结合并使其呈阳性)，虽然FTA-Abs对于梅毒抗体检测更具有特异性，但使用重组抗原不会出现假阳性。</p></div></div><div id="par_14996343428743687"><h2 class="title">5 治疗<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>通常，给予阿司匹林抑制血小板活化和/或华法林抗凝治疗抗磷脂综合征。华法林预防性治疗的目标是将患者的INR维持在2.0至3.0之间<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_10" class="kx_ref">[10]</a></sup>。无血栓形成症状的病人不会常规使用。</p><p>在妊娠妇女中，抗凝可以防止流产<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_11" class="kx_ref">[11]</a></sup>。 由于华法林具有致畸性，在妊娠妇女中选择低分子肝素和低剂量阿司匹林代替华法林<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_12" class="kx_ref">[12]</a></sup>，建议复发性流产的妇女在非月经期选择阿司匹林和低分子肝素治疗。在难治性病例中，可以使用血浆置换。</p></div></div><div id="par_14996343428743688"><h2 class="title">6 预后<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>APS的长期预后主要取决于血栓形成的复发，有些患者即使采用抗凝治疗，复发率仍高达29%。</p></div></div><div id="par_14996343428743689"><h2 class="title">7 历史<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>抗磷脂综合征在20世纪80年代由奈杰尔·哈里斯和阿齐兹·加拉维完整描述。他们在1983年发表了第一篇论文<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_13" class="kx_ref">[13]</a></sup><sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_14" class="kx_ref">[14]</a></sup>。该综合征也被风湿病学家格雷厄姆·休斯(英国伦敦圣托马斯医院)及其同事中称为“Hughes综合征”。</p></div></div><div id="par_14996343445520896"><h2 class="title">8 研究<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>APS ACTION(抗磷脂综合征临床试验和国际网络联盟)是第一个国际研究网络联盟，旨在抗磷脂抗体(aPL)持续阳性患者中设计和进行大规模多中心临床试验<sup><a href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/d11121.htm#quote_15" class="kx_ref">[15]</a></sup>。 该网络联盟由来自世界各地对抗磷脂综合征研究感兴趣的多学科医生和研究者组成。APS ACTION的主要任务是通过高质量、多中心和多学科的临床研究来预防、治疗和治愈抗磷脂抗体(aPL)相关的临床疾病。</p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Aps | Action". Apsaction.org. Archived from the original on 2013-07-25. Retrieved 2013-11-06..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lupus and Pregnancy Archived 2013-02-18 at the Wayback Machine by Michelle Petri. The Johns Hopkins Lupus Center. Retrieved May 2011.</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Rinne T, Bronstein AM, Rudge P, Gresty MA, Luxon LM (1998). "Bilateral loss of vestibular function: clinical findings in 53 patients". J. Neurol. 245 (6–7): 314–21. doi:10.1007/s004150050225. PMID 9669481..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sokol DK, O'Brien RS, Wagenknecht DR, Rao T, McIntyre JA (2007). "Antiphospholipid antibodies in blood and cerebrospinal fluid of patients with psychosis". Journal of Neuroimmunology. 190 (1): 151–6. doi:10.1016/j.jneuroim.2007.08.002. PMID 17868908..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Triplett DA (November 2002). "Antiphospholipid antibodies". Archives of Pathology &amp; Laboratory Medicine. 126 (11): 1424–9. doi:10.1043/0003-9985(2002)126&lt;1424:AA&gt;2.0.CO;2 (inactive 2019-03-20). PMID 12421152..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Rand JH (1998). "Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms". The American Journal of the Medical Sciences. 316 (2): 142–51. doi:10.1097/00000441-199808000-00009. PMID 9704667..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tong, M.; Viall, C. A.; Chamley, L. W. (2014). "Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment". Human Reproduction Update. 21 (1): 97–118. doi:10.1093/humupd/dmu049. PMID 25228006..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (February 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". J. Thromb. Haemost. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. PMID 16420554..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y (2003). "Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines". Lupus. 12 (7): 530–4. doi:10.1191/0961203303lu394oa. PMID 12892393..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Horton JD, Bushwick BM (1999). "Warfarin therapy: evolving strategies in anticoagulation". American Family Physician. 59 (3): 635–46. PMID 10029789..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">de Jong PG, Goddijn M, Middeldorp S (2013). "Antithrombotic therapy for pregnancy loss". Human Reproduction Update. 19 (6): 656–673. doi:10.1093/humupd/dmt019. PMID 23766357..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Archived copy" (PDF). Archived (PDF) from the original on 2016-03-23. Retrieved 2016-03-17.CS1 maint: Archived copy as title (link).</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (October 2010). "Antiphospholipid syndrome". Lancet. 376 (9751): 1498–509. doi:10.1016/S0140-6736(10)60709-X. PMID 20822807..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hughes GR (October 1983). "Thrombosis, abortion, cerebral disease, and the lupus anticoagulant". Br. Med. J. (Clin. Res. Ed.). 287 (6399): 1088–9. doi:10.1136/bmj.287.6399.1088. PMC 1549319. PMID 6414579..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M (2011). "Antiphospholipid Syndrome Clinical Research Task Force Report". Lupus. 20 (2): 219–224. doi:10.1177/0961203310395053. PMID 21303838..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->515</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221029032955/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221029032955/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221029032955/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221029032955/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"11121","versionId":"52058398732110091","title":"抗磷脂综合征","subtitle":"","abstracts":{"paragraphId":"52058398765664523","title":"摘要","versionId":"52058398732110092","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p><b>抗磷脂综合征或抗磷脂抗体综合征(APS或APLS)</b>，是由抗磷脂抗体引起的自身免疫性高凝状态。APS导致动静脉血栓形成以及妊娠相关并发症，如流产、死产、早产和重度子痫前期。诊断标准需要一个临床表现(即血栓形成或妊娠并发症)和两项相隔至少三个月的血清抗体实验室检查，包括狼疮抗凝物或抗β2-糖蛋白-1(由于β2-糖蛋白-1抗体属于抗心磷脂抗体，抗心磷脂试验可以作为替代实验)<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup>。</p>\n<p>抗磷脂综合征分为原发性和继发性。原发性抗磷脂综合征是指没有任何其他相关疾病所致的抗磷脂综合征。继发性抗磷脂综合征继发于其他自身免疫性疾病，如系统性红斑狼疮。在极少数情况下，APS会因全身血栓形成而导致快速器官衰竭；被称为“灾难性抗磷脂综合征”(CAPS或Asherson综合征)，与高死亡风险相关。</p>\n<p>抗磷脂综合征通常需要采用抗凝药物进行治疗，如肝素，以降低进一步血栓形成的风险，并改善妊娠预后。与肝素不同，妊娠期间，不使用华法林/香豆素，因为它可以穿过胎盘，并且具有致畸作用。</p>","pics":null,"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":"","versionId":"0","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":"","pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":13,"name":"药学","parents":[]}],"creator":{"uid":76032588,"name":"朱丹","pic":"https://web.archive.org/web/20221029032955/https://cache.soso.com/qlogo/g?b=oidb&k=yrSO6VsQ7mjpcz0B3v2Ruw&s=100&t=1555724637","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":1571038604,"editor":{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221029032955/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true},"editTime":1598325223,"state":1,"versionCount":2,"upNum":1,"downNum":0,"pics":[],"catalogs":[{"level":1,"title":"症状和体征","paragraphId":"14996343411966475","subCatalogs":null},{"level":1,"title":"风险因素","paragraphId":"14996343411966476","subCatalogs":null},{"level":1,"title":"发病机制","paragraphId":"14996343411966477","subCatalogs":null},{"level":1,"title":"诊断","paragraphId":"14996343411966478","subCatalogs":[{"level":2,"title":"<b>狼疮抗凝物</b>","paragraphId":"14996343411966478","subCatalogs":null},{"level":2,"title":"<b>抗心磷脂抗体</b>","paragraphId":"14996343411966478","subCatalogs":null},{"level":2,"title":"<b>诊断标准</b>","paragraphId":"14996343411966478","subCatalogs":null}]},{"level":1,"title":"治疗","paragraphId":"14996343428743687","subCatalogs":null},{"level":1,"title":"预后","paragraphId":"14996343428743688","subCatalogs":null},{"level":1,"title":"历史","paragraphId":"14996343428743689","subCatalogs":null},{"level":1,"title":"研究","paragraphId":"14996343445520896","subCatalogs":null},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14996343411966475","title":"症状和体征","versionId":"52058398732110093","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>在没有血栓或妊娠相关并发症的情况下，抗磷脂抗体(aPL)阳性不能诊断APS(APS的诊断见下文)。抗磷脂综合征可在任何器官系统中引起动脉或静脉血栓，或妊娠相关并发症。APS患者中，最常见的静脉血栓是下肢深静脉血栓形成，最常见的动脉血栓是卒中。在受APS影响的孕妇中，反复流产、宫内生长受限和早产的风险增加。这些并发症的常见原因是胎盘梗塞。在某些情况下，APS是新生儿智力和/或发育迟缓的主要原因，机制是aPL抑制滋养层细胞的分化。在妊娠合并系统性红斑狼疮的患者中，抗磷脂综合征是大多数妊娠晚期流产的原因<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>。</p><p>其他常见的临床，虽然不属于APS诊断标准的一部分，但包括血小板计数减少、心脏瓣膜疾病和网状青斑。抗磷脂抗体也可以引起头痛、偏头痛和振动幻视<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup>。一些研究表明，有神经精神症状的患者血液和脑脊液中存在抗磷脂抗体<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup>。</p><p>很少有原发性抗磷脂抗体综合征患者继续发展成系统性红斑狼疮。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343411966476","title":"风险因素","versionId":"52058398732110094","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>抗磷脂综合征的危险因素包括:</p><p>\n <ul>\n  <li>原发性APS\n   <ul>\n    <li>遗传标记 HLA-DR7</li>\n   </ul></li>\n  <li>继发性APS\n   <ul>\n    <li>系统性红斑狼疮或其他自身免疫性疾病</li>\n    <li>遗传标记:人类白细胞抗原-B8，人类白细胞抗原-DR2，人类白细胞抗原-DR3</li>\n    <li>种族:黑人、西班牙裔、亚洲人和美洲原住民</li>\n   </ul></li>\n </ul></p><p>肾上腺出血导致沃特豪斯-弗里德里希森综合征(脑膜炎奈瑟菌引起原发性肾上腺功能不全)的风险增加。这需要终身采用肾上腺类固醇替代治疗。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343411966477","title":"发病机制","versionId":"52058398732110095","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>抗磷脂综合征是一种自身免疫性疾病，其中“抗磷脂抗体”(抗心磷脂抗体和狼疮抗凝物抗体)与细胞膜上带负电荷磷脂的蛋白质发生反应。像许多自身免疫性疾病一样，女性比男性更常见。确切原因尚不清楚，但凝血系统的激活是明确的。临床上重要的抗磷脂抗体(由自身免疫过程产生的抗体)与血栓形成和血管疾病相关。该综合征可分为原发性(无原发病)和继发性(与原发病相关)。</p><p>抗ApoH和一些抗心磷脂抗体与ApoH结合，进而抑制蛋白C，蛋白C是凝血共同通路途径上具有调节功能的糖蛋白(降解活化V因子)。</p><p>凝血酶是凝血酶原的活性形式，狼疮抗凝物抗体结合凝血酶原，从而增加其对凝血酶的裂解。</p><p>在APS中也有抗体结合蛋白S，蛋白S是蛋白C的一个协同因子。因此，抗蛋白S抗体能降低蛋白C的活性<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>。</p><p>膜联蛋白A5在带负电荷的磷脂分子周围形成屏障，从而抑制凝血。因此，抗膜联蛋白A5抗增强了磷脂依赖性凝血过程<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup>。</p><p>狼疮抗凝物抗体与血栓形成密切相关，其中靶向β2糖蛋白1的抗体比靶向凝血酶原的抗体与血栓形成关系更密切。抗心磷脂抗体在中高滴度(&gt; 40GPLU或MPLU)时与血栓形成相关。狼疮抗凝物抗体和中/高滴度抗心磷脂抗体的患者比单一抗体的患者血栓形成风险更高。</p><p>体外研究证实，抗磷脂抗体导致反复流产、宫内生长受限和早产的风险增加，包括滋养层细胞活性、合胞体化和侵袭功能降低、滋养层激素和信号分子的紊乱，以及凝血和补体途径的激活<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup>。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343411966478","title":"诊断","versionId":"52058398732110096","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>抗磷脂综合征的抗体实验室检查分别采用液相凝血试验(狼疮抗凝物)和固相酶联免疫吸附试验(抗心磷脂抗体)。</p><p>遗传性血栓形成倾向是APS鉴别诊断的一部分，在一些APS患者中可以共存。遗传性血栓形成倾向可能需要抗凝治疗。因此，遗传性血栓形成倾向筛查可包括:</p><p>\n <ul>\n  <li>进一步研究莱顿V因子变异体和凝血酶原G20210A突变，VIII因子水平，甲氨蝶呤突变。</li>\n  <li>l 蛋白C、游离蛋白和总蛋白S、VIII因子、抗凝血酶、纤溶酶原、组织纤溶酶原激活物（TPA）和纤溶酶原激活物抑制剂-1(PAI-1)的水平。</li>\n </ul></p><p>抗aPL的个体靶标如β2糖蛋白1和抗磷脂酰丝氨酸的抗体检测目前正在争论中，因为目前抗心磷脂的检测对APS的诊断是敏感和特异的，虽然抗心磷脂抗体在体内并不被认为是抗磷脂抗体的靶标。</p><p><h3><b>狼疮抗凝物</b></h3></p><p>由于狼疮抗凝物抗体的异质性，至少通过使用两种磷脂敏感的凝血试验来检测。通常在初始筛查的患者中APTT会有延长，延长的APTT在与正常人血浆的80∶20混合物中不能被修正(与正常血浆的50∶50混合物，除了对最高抗体水平敏感外，其余所有抗体水平都不敏感)。APTT(加80:20混合比例)、Russell蝰蛇毒液稀释时间(DRVVT)、白陶土凝固时间(KCT)、稀释凝血活酶时间(TDT/DTT)、二氧化硅凝固时间(SCT)<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 和凝血酶原时间(使用狼疮敏感凝血活酶)是用于检测狼疮抗凝物的主要实验。这些检测必须至少进行两次且间隔至少6周，每次均阳性，才能诊断抗磷脂综合征。这是为了防止一过性的阳性结果(由于感染等原因)被被误诊为抗磷脂综合征。</p><p>将狼疮抗体与特定凝血因子抑制剂(如VIII因子)区分开来，通常是通过测定狼疮抗凝物与特定凝血因子抗体对凝血因子影响的区别来实现的。狼疮抗凝物将抑制所有接触激活凝血途径因子(VIII因子、IX因子、XI因子和XII因子)。狼疮抗凝物很少导致凝血因子水平低于35 iu/dl (35%)，而特定凝血因子抗体则很少高于10 iu/dl (10%)。由于狼疮抗凝物对凝血功能的影响，可以采用APTT比监测静脉抗凝剂治疗效果，在这些情况下，采用肝素介导的抗凝血酶对Xa因子的抑制显色的检测方法是最好的。</p><p><h3><b>抗心磷脂抗体</b></h3></p><p>抗心磷脂抗体可采用酶联免疫吸附试验(ELISA)进行检测，该试验筛选β2糖蛋白1依赖性抗心磷脂抗体。</p><p>在抗心磷脂阳性患者中中也可以观察到血小板计数减少和抗β2-糖蛋白1或磷脂酰丝氨酸抗体的阳性。</p><p><h3><b>诊断标准</b></h3></p><p>APS的诊断标准需要一个或多个特定的、确切的临床表现(血栓形成和/或产科不良事件)和aPL重复阳性的实验室结果。APS札幌诊断标准(1998年，1999年出版)在2006年被悉尼标准取代<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>。根据最新标准，APS的诊断需要一种临床表现和一种实验室结果:</p><p>\n <ul>\n  <li>临床表现\n   <ul>\n    <li>依据客观诊断标准，任何组织或器官中动脉、静脉或小血管血栓形成(浅静脉血栓形成除外)，且无血管炎表现。</li>\n    <li>1次或以上形态正常胎儿(通过超声或胎儿直接检查确诊)在妊娠第10周或之后不明原因死亡，和/或排除母体解剖或激素异常以及父系和母系染色体原因，3次或以上妊娠第10周之前不明原因连续自然流产，或至少1次形态正常新生儿在妊娠第34周之前因子痫或重度子痫前期早产，或胎盘功能不全。</li>\n   </ul></li>\n  <li>实验室检查:\n   <ul>\n    <li>用标准化的酶联免疫吸附测定法测定抗心磷脂抗体，IgG&nbsp; 和/或IgM抗体2次或更多次，间隔不少于12周，结果为中高滴度(即&gt; 40 GPL 或 MP，L或&gt;第99百分位)</li>\n    <li>用标准化酶联免疫吸附试验测定抗β2糖蛋白抗体，IgG和/或IgM 2次或更多次，间隔不少于12周，结果为中高滴度(&gt;第99百分位)</li>\n    <li>根据国际血栓形成和止血学会指南，狼疮抗凝物检测间隔不少于12周。</li>\n   </ul></li>\n </ul></p><p>APS分为三类:原发性(不伴有其他疾病)、继发性(既往有自身免疫性疾病，最常见的是系统性红斑狼疮(SLE))和灾难性(伴随多器官功能衰竭和小血管闭塞)。</p><p>根据2006年的共识<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>，出于研究目的，建议将APS按如下标准分类:</p><p>\n <ul>\n  <li>I:一个以上的实验室诊断标准；</li>\n  <li>IIa:狼疮抗凝物单独存在</li>\n  <li>IIb:中高度抗心磷脂IgG和/或IgM单独存在</li>\n  <li>IIc:抗β2糖蛋白IgG和/或IgM单独存在，滴度大于99%</li>\n </ul></p><p>该国际共识通常用于灾难性APS诊断<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup>。基于这一共识，CAPS诊断包括以下标准:</p><p>\n <ul>\n  <li>三个或更多器官或组织中血栓形成</li>\n  <li>同时或在不到一周的时间内出现临床症状</li>\n  <li>至少一个器官或组织中有小血管血栓形成的表现</li>\n  <li>实验室确诊aPL阳性。</li>\n </ul></p><p>VDRL，用于检测梅毒抗体的实验，在aPL阳性患者中可能会有假阳性结果(aPL在检测中与脂质结合并使其呈阳性)，虽然FTA-Abs对于梅毒抗体检测更具有特异性，但使用重组抗原不会出现假阳性。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343428743687","title":"治疗","versionId":"52058398732110097","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>通常，给予阿司匹林抑制血小板活化和/或华法林抗凝治疗抗磷脂综合征。华法林预防性治疗的目标是将患者的INR维持在2.0至3.0之间<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup>。无血栓形成症状的病人不会常规使用。</p><p>在妊娠妇女中，抗凝可以防止流产<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup>。 由于华法林具有致畸性，在妊娠妇女中选择低分子肝素和低剂量阿司匹林代替华法林<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup>，建议复发性流产的妇女在非月经期选择阿司匹林和低分子肝素治疗。在难治性病例中，可以使用血浆置换。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343428743688","title":"预后","versionId":"52058398732110098","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>APS的长期预后主要取决于血栓形成的复发，有些患者即使采用抗凝治疗，复发率仍高达29%。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343428743689","title":"历史","versionId":"52058398732110099","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>抗磷脂综合征在20世纪80年代由奈杰尔·哈里斯和阿齐兹·加拉维完整描述。他们在1983年发表了第一篇论文<sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup><sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup>。该综合征也被风湿病学家格雷厄姆·休斯(英国伦敦圣托马斯医院)及其同事中称为“Hughes综合征”。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996343445520896","title":"研究","versionId":"52058398732110100","lemmaId":11121,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":5567290,"name":"″ Μιán²","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598325223,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>APS ACTION(抗磷脂综合征临床试验和国际网络联盟)是第一个国际研究网络联盟，旨在抗磷脂抗体(aPL)持续阳性患者中设计和进行大规模多中心临床试验<sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup>。 该网络联盟由来自世界各地对抗磷脂综合征研究感兴趣的多学科医生和研究者组成。APS ACTION的主要任务是通过高质量、多中心和多学科的临床研究来预防、治疗和治愈抗磷脂抗体(aPL)相关的临床疾病。</p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"\"Aps | Action\". Apsaction.org. Archived from the original on 2013-07-25. Retrieved 2013-11-06.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"Lupus and Pregnancy Archived 2013-02-18 at the Wayback Machine by Michelle Petri. The Johns Hopkins Lupus Center. Retrieved May 2011","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Rinne T, Bronstein AM, Rudge P, Gresty MA, Luxon LM (1998). \"Bilateral loss of vestibular function: clinical findings in 53 patients\". J. Neurol. 245 (6–7): 314–21. doi:10.1007/s004150050225. PMID 9669481.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"Sokol DK, O'Brien RS, Wagenknecht DR, Rao T, McIntyre JA (2007). \"Antiphospholipid antibodies in blood and cerebrospinal fluid of patients with psychosis\". Journal of Neuroimmunology. 190 (1): 151–6. doi:10.1016/j.jneuroim.2007.08.002. PMID 17868908.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"Triplett DA (November 2002). \"Antiphospholipid antibodies\". Archives of Pathology & Laboratory Medicine. 126 (11): 1424–9. doi:10.1043/0003-9985(2002)126<1424:AA>2.0.CO;2 (inactive 2019-03-20). PMID 12421152.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Rand JH (1998). \"Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms\". The American Journal of the Medical Sciences. 316 (2): 142–51. doi:10.1097/00000441-199808000-00009. PMID 9704667.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Tong, M.; Viall, C. A.; Chamley, L. W. (2014). \"Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment\". Human Reproduction Update. 21 (1): 97–118. doi:10.1093/humupd/dmu049. PMID 25228006.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (February 2006). \"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)\". J. Thromb. Haemost. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. PMID 16420554.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y (2003). \"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines\". Lupus. 12 (7): 530–4. doi:10.1191/0961203303lu394oa. PMID 12892393.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Horton JD, Bushwick BM (1999). \"Warfarin therapy: evolving strategies in anticoagulation\". American Family Physician. 59 (3): 635–46. PMID 10029789.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"de Jong PG, Goddijn M, Middeldorp S (2013). \"Antithrombotic therapy for pregnancy loss\". Human Reproduction Update. 19 (6): 656–673. doi:10.1093/humupd/dmt019. PMID 23766357.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"\"Archived copy\" (PDF). Archived (PDF) from the original on 2016-03-23. Retrieved 2016-03-17.CS1 maint: Archived copy as title (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (October 2010). \"Antiphospholipid syndrome\". Lancet. 376 (9751): 1498–509. doi:10.1016/S0140-6736(10)60709-X. PMID 20822807.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Hughes GR (October 1983). \"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant\". Br. Med. J. (Clin. Res. Ed.). 287 (6399): 1088–9. doi:10.1136/bmj.287.6399.1088. PMC 1549319. PMID 6414579.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M (2011). \"Antiphospholipid Syndrome Clinical Research Task Force Report\". Lupus. 20 (2): 219–224. doi:10.1177/0961203310395053. PMID 21303838.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":515,"auditType":2,"synonyms":null,"showEditTime":"2020.08.25 11:13","auditors":[{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221029032955/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true}],"hasZhishiNav":false,"auditInfos":{"0":[{"versionId":"0","auditTime":1598325411,"auditorId":5567290,"auditUser":{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221029032955/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true},"auditReason":"","auditSuggest":"简单修改","auditResult":2,"auditAnnotations":null}]},"isHistory":false};</script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1121.抗磷脂综合征 - 搜狗科学百科_files/main_edf0f08.js.download"></script>
</body></html>